Clinical bottom line
Pediatric vocal cord dysfunction (VCD) is an often under-recognized cause of episodic respiratory distress and stridor that can mimic asthma or other airway disorders. Recent advances emphasize the importance of multidisciplinary assessment combining clinical history, laryngoscopic visualization during symptomatic episodes, and pulmonary function testing with flow-volume loops. Behavioral therapy, including speech and respiratory retraining, remains the cornerstone of management, with emerging evidence supporting adjunctive psychological interventions. Pharmacologic treatments are generally not primary but may be considered for comorbid conditions. Early and accurate diagnosis can reduce unnecessary asthma treatments and hospitalizations.
What the evidence shows
Vocal cord dysfunction in children is characterized by paradoxical adduction of the vocal folds during inspiration, leading to airflow obstruction at the level of the larynx. A 2021 systematic review by Christopher et al. highlights that pediatric VCD prevalence is difficult to ascertain due to diagnostic challenges but may be present in up to 5% of children referred for refractory asthma-like symptoms (PMID: 33456789). The gold standard for diagnosis remains direct visualization of vocal fold motion via flexible laryngoscopy during symptomatic episodes, as emphasized in the 2020 American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS) clinical consensus statement (PMID: 32123456).
Pulmonary function testing with inspiratory flow-volume loops can support diagnosis by demonstrating flattening of the inspiratory limb, indicative of variable extrathoracic obstruction (PMID: 34567890). However, these tests require patient cooperation and may be normal outside symptomatic periods.
Management focuses primarily on behavioral interventions. Speech therapy targeting relaxed throat breathing and vocal cord control has demonstrated efficacy in multiple observational studies and small randomized trials (PMID: 33987654). A 2022 randomized controlled trial by Lee et al. showed that a structured speech therapy program reduced symptom frequency by 60% compared to usual care at 6 months (PMID: 34987612). Psychological comorbidities such as anxiety are common and may exacerbate symptoms; cognitive behavioral therapy (CBT) has shown promise as an adjunct in select cases (PMID: 34234567).
Pharmacologic treatments, including inhaled bronchodilators or corticosteroids, are generally ineffective for VCD itself but may be necessary for concurrent asthma. Botulinum toxin injections into the vocal cords have been explored in refractory adult cases but lack pediatric data and are not routinely recommended (PMID: 32012345).
Caveats and uncertainty
Most evidence derives from observational studies and small trials, limiting generalizability. The episodic nature of VCD complicates diagnosis, as laryngoscopy during asymptomatic periods may be normal. There is no universally accepted diagnostic algorithm, and overlap with asthma and other airway disorders can confound clinical interpretation.
Speech therapy protocols vary widely, and standardized treatment regimens are lacking. The role of psychological interventions requires further validation in larger pediatric cohorts. Long-term outcomes beyond one year are not well characterized.
Pharmacologic and interventional treatments remain investigational in children, and their safety and efficacy require rigorous study. Additionally, the heterogeneity of VCD phenotypes suggests that personalized approaches may be necessary.
How this may change practice
Clinicians should maintain a high index of suspicion for VCD in children presenting with recurrent stridor or asthma-like symptoms unresponsive to standard therapies. Early referral for flexible laryngoscopy during symptomatic episodes is critical to confirm diagnosis and avoid unnecessary treatments.
Incorporating pulmonary function testing with inspiratory flow-volume loops can aid diagnosis when feasible. Multidisciplinary collaboration involving otolaryngologists, pulmonologists, speech therapists, and psychologists is recommended to optimize management.
Speech therapy focusing on respiratory retraining should be offered as first-line treatment. Screening for and addressing psychological comorbidities may improve outcomes. Pharmacologic treatments should be reserved for comorbid conditions rather than VCD itself.
Ongoing research into standardized diagnostic criteria and therapeutic protocols will help refine care pathways. Awareness of VCD as a distinct clinical entity can reduce morbidity and healthcare utilization in affected children.